Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFallopian tube cancer added to the study keywords; the record revision updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check19 days agoChange DetectedAdded Primary peritoneal carcinoma to the terminology and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 on the page header.SummaryDifference0.0%

- Check70 days agoChange DetectedLocations were consolidated into one Locations section with individual state subsections (California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania). This update is part of revision v3.3.3.SummaryDifference0.6%

- Check91 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check98 days agoChange DetectedDeleted the generic government funding/operating status notice; the study content and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.